Porównaj metody
Przeglądaj wybrane metody obok siebie; wiersze, które się różnią, są wyróżnione.
| Skala Objawów Nienapędowych w Chorobie Parkinsona (NMSS)× | Zmodyfikowana Skala Rankina (mRS)× | |
|---|---|---|
| Dziedzina | Neurologia | Neurologia |
| Rodzina | Process / pipeline | Process / pipeline |
| Rok powstania≠ | 2007 | 1988 |
| Twórca≠ | K. Ray Chaudhuri, National Hospital for Neurology and Neurosurgery, London | Rankin scale original (Rankin, 1957); modified version by van Swieten et al. |
| Typ≠ | Self-report questionnaire and clinician interview | Clinician-rated ordinal scale |
| Źródło pierwotne≠ | Chaudhuri, K. R., Martinez-Martin, P., Brown, R. G., Sethi, K., Stocchi, F., Odin, P., Ondo, W., Whone, A., Rye, D., Bhattacharya, K., Naidu, Y., Schapira, A. H., Brozova, H., Nutt, J., Macphee, G., Carroll, C., Hilten, J. V., Verschuuren, J., & Bonuccelli, U. (2007). The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study. Movement Disorders, 22(13), 1901-1911. DOI ↗ | van Swieten, J. C., Koudstaal, P. J., Visser, M. C., Schouten, H. J., & van Gijn, J. (1988). Interobserver agreement for the assessment of handicap in stroke patients. Stroke, 19(5), 604-607. DOI ↗ |
| Inne nazwy | Parkinson's Non-Motor Scale, NMSQ, NMS Scale | mRS, Rankin Scale, Modified Rankin |
| Pokrewne | 4 | 4 |
| Podsumowanie≠ | The NMSS is a comprehensive 30-item scale designed to assess the prevalence and impact of non-motor symptoms (NMS) in Parkinson's disease. Developed by Chaudhuri and colleagues in 2007, it addresses the reality that non-motor features—sleep disorders, mood disturbances, autonomic dysfunction, cognitive impairment, and pain—often cause greater disability and suffering than motor symptoms in many PD patients. The scale is essential for comprehensive PD assessment and is increasingly recognized as a critical outcome measure reflecting true patient burden. | The Modified Rankin Scale is a simple 0-6 ordinal measure of global disability or dependency in patients with stroke and other neurological conditions. Originally developed by Rankin in 1957 and modified by van Swieten and colleagues in 1988, it remains the most widely used global disability outcome in stroke clinical trials and clinical practice. Its simplicity, brevity, and strong prognostic association make it the gold standard for acute stroke outcome measurement and is mandated as a primary endpoint in virtually all stroke therapeutic trials. |
| ScholarGateZbiór danych ↗ |
|
|